Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMX0035 in ALS
NCT03127514Phase 2Completed
- Sponsor
- Amylyx Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sodium phenylbutyrate in amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Amylyx Pharmaceuticals. Primary endpoints: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Slope Change at 24 weeks, Number of Participants With Adverse Events at 24 weeks and 1 more. Started Jun 2017; status: completed.
02
Drugs
sodium phenylbutyrate
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03127514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127514.